Functionalized liposomes for targeted breast cancer drug delivery

Bioactive Materials, Journal Year: 2023, Volume and Issue: 24, P. 401 - 437

Published: Jan. 2, 2023

Despite the exceptional progress in breast cancer pathogenesis, prognosis, diagnosis, and treatment strategies, it remains a prominent cause of female mortality worldwide. Additionally, although chemotherapies are effective, they associated with critical limitations, most notably their lack specificity resulting systemic toxicity eventual development multi-drug resistance (MDR) cells. Liposomes have proven to be an invaluable drug delivery system but multitudes liposomal systems developed every year only few been approved for clinical use, none which employ active targeting. In this review, we summarize recent strategies actively targeted surface, transmembrane internal cell receptors, enzymes, direct targeting dual-targeting cancer-associated cells, e.g., stem cells tumor microenvironment, etc.

Language: Английский

---

Recent advances in drug delivery systems for targeting brain tumors

Drug Delivery, Journal Year: 2023, Volume and Issue: 30(1), P. 1 - 18

Published: Jan. 3, 2023

Brain tumor accounts for about 1.6% of incidence and 2.5% mortality all tumors, the median survival brain patients is only 20 months. The treatment still faces many challenges, such as blood-brain barrier (BBB), (BBTB), overexpressed efflux pumps, infiltration, invasion, high heterogeneity cells, drug resistance immune escape caused by microenvironment (TME) cancer stem cells (CSC). This review attempts to clarify challenges multi-functional nano delivery systems (NDDS) cross BBB target or organelles, also provides a brief description different types targeted NDDS that have shown potential success in delivering drugs brain. Further, this summarizes research progress combination therapy tumors from following sections, chemotherapy drugs, chemotherapy-chemodynamic therapy, chemotherapy-immunization chemotherapy-gene therapy. We provide an insight into recent advances designing

Language: Английский

---

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2021, Volume and Issue: 1877(1), P. 188645 - 188645

Published: Nov. 16, 2021

Language: Английский

---

Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer

Journal of Controlled Release, Journal Year: 2021, Volume and Issue: 341, P. 498 - 510

Published: Dec. 6, 2021

Language: Английский

---

Emerging targeted drug delivery strategies toward ovarian cancer

Advanced Drug Delivery Reviews, Journal Year: 2021, Volume and Issue: 178, P. 113969 - 113969

Published: Sept. 9, 2021

Language: Английский

---

Chemical Approaches to Synthetic Drug Delivery Systems for Systemic Applications

Angewandte Chemie International Edition, Journal Year: 2022, Volume and Issue: 61(49)

Published: May 16, 2022

Poor water solubility and low bioavailability of active pharmaceutical ingredients (APIs) are major causes friction in the industry represent a formidable hurdle for drug development. Drug delivery remains challenge application new small-molecule drugs as well biopharmaceuticals. The three challenges synthetic systems are: (i) controlling distribution clearance blood; (ii) solubilizing poorly water-soluble agents, (iii) selectively targeting specific tissues. Although several polymer-based have addressed first two demands been translated into clinical practice, no targeted system has reached market. This Review is designed to provide background on requirements design translation systems. report will focus chemical approaches systemic applications.

Language: Английский

---

Mitochondrial dysfunction-targeted nanosystems for precise tumor therapeutics

Biomaterials, Journal Year: 2022, Volume and Issue: 293, P. 121947 - 121947

Published: Dec. 6, 2022

Language: Английский

---

“Targeting Design” of Nanoparticles in Tumor Therapy

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(9), P. 1919 - 1919

Published: Sept. 11, 2022

Tumor-targeted therapy based on nanoparticles is a popular research direction in the biomedical field. After decades of and development, both passive targeting ability inherent properties NPs active ligand receptor interaction have gained deeper understanding. Unfortunately, most targeted delivery strategies are still preclinical trial stage, so it necessary to further study biological fate particles vivo mechanism with tumors. This article reviews different NPs, focuses physical chemical (size, morphology, surface intrinsic properties), ligands (binding number/force, activity species) receptors (endocytosis, distribution recycling) other factors that affect particle targeting. The limitations solutions these discussed, variety new schemes introduced, hoping provide guidance for future design achieve purpose rapid transformation into clinical application.

Language: Английский

---

Nanomedicine Combats Drug Resistance in Lung Cancer

Advanced Materials, Journal Year: 2023, Volume and Issue: 36(3)

Published: Nov. 16, 2023

Lung cancer is the second most prevalent and leading cause of cancer-related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, radiotherapy are currently available as treatment methods. However, drug resistance a significant factor in failure lung treatments. Novel therapeutics have been exploited to address complicated mechanisms advancement nanomedicine extremely promising terms overcoming resistance. Nanomedicine equipped with multifunctional tunable physiochemical properties alignment tumor genetic profiles can achieve precise, safe, effective while minimizing or eradicating cancer. Here, this work reviews discovered for radiotherapy, outlines novel strategies development against This focuses on engineering design, customized delivery, current challenges, clinical translation application resistant

Language: Английский

---

Photoactivated DNA Nanodrugs Damage Mitochondria to Improve Gene Therapy for Reversing Chemoresistance

ACS Nano, Journal Year: 2023, Volume and Issue: 17(17), P. 16923 - 16934

Published: Aug. 22, 2023

Multidrug resistance (MDR) is a major cause of chemotherapy failure in oncology, and gene therapy an excellent measure to reverse MDR. However, conventional only modulates the expression MDR-associated proteins but hardly affects their existing function, thus limiting efficiency tumor treatment. Herein, we designed photoactivated DNA nanodrug (MCD@TMPyP4@DOX) improve chemosensitivity through downregulation MDR-related genes mitochondria-targeted photodynamic (PDT). The self-assembled encodes mucin 1 (MUC1) aptamer cytochrome C (CytC) facilitate its selective targeting mitochondria cells; encoded P-gp DNAzyme can specifically cleave substrate silence MDR1 mRNA with help Mg2+ cofactors. Under near-infrared (NIR) light irradiation, PDT generates reactive oxygen species (ROS) that precisely damage cells break single-stranded (ssDNA) activate MCD@TMPyP4@DOX self-disassembly for release DOX DNAzyme. We have demonstrated this multifunctional has high drug delivery capacity biosafety. It enables while reducing ATP on which pumps out drugs, improving latency synergistically efflux sensitize chemotherapy. envision gene-modulating based damaging expected provide important perspective sensitizing

Language: Английский

---